Objective: To assess left ventricular (LV) geometry, LV diastolic and systolic function in maintenance hemodialysis uremic patients.
Methods: Forty uremic patients and forty-five normal subjects were included in this study. LV volume, LV mass index (LVMI), relative wall thickness (RWT), LV mass and diastolic volume ratio (LVM/EDV) were measured. Mitral flow E velocity and A velocity ratio, deceleration time, mitral flow E velocity and mitral annulus Ea velocity ratio (E/Ea), pulmonary vein flow S velocity and D velocity ratio, atrial flow reversal velocity of pulmonary vein flow, mitral inflow propagation velocity, left atrium volume (LAV) and pulmonary artery systolic pressure (PASP) were determined for diastolic function evaluation. LV ejection fraction (LVEF) and single volume (SV) were derived from 3D echocardiography, systolic velocity of mitral valve annulus (Sa) by pulse tissue Doppler imaging (TDI) were used to evaluate systolic function. The time to peak systolic velocity (Ts) and early diastole velocity (Td) of LV 12 segments were measured using TDI. The maximal difference of Ts and Td (Ts-Dif and Td-Dif) were calculated to assess LV systolic and diastolic asynchrony.
Results: RWT, LVMI and LVM/EDV were significantly increased in uremic patients. There were 50% concentric, 17.5% eccentric hypertrophy and 17.5%concentric remodeling, respectively in uremic patients. The indices for LV diastolic function (E/Ea, LAV and PASP) were significantly higher in uremic patients than those in control subjects (P < 0.01). About 85% of the diastolic dysfunction in uremic patients presented as impaired relaxation pattern and 32.5% as increased filling pressure. LVEF and SV were similar between uremic patients and control subjects. Sa was significantly lower in uremic group than that in controls (P < 0.05). Ts-Dif was similar between the 2 groups while Td-Dif was significantly higher in uremic patients than control subjects (P < 0.05).
Conclusion: LV hypertrophy, LV mass increase and LV diastolic dysfunction were the major characteristic of myocardial injury in uremia patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A compound heterozygous mutation causes congenital thrombotic thrombocytopenic purpura: a case report.
Front Med (Lausanne)
January 2025
Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Congenital thrombotic thrombocytopenic purpura (cTTP) is a thrombotic microangiopathy (TMA) characterized by severe hereditary ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) deficiency caused by mutations. This rare autosomal recessive genetic disorder is often misdiagnosed as immune thrombocytopenia (ITP) or hemolytic uremic syndrome (HUS). Here, we report a 21-year-old male cTTP patient with a compound heterozygous mutation.
View Article and Find Full Text PDFCluster of symptoms in kidney failure: A systematic review.
Heliyon
January 2025
Institute of Biomedicine of Málaga (IBIMA), 29010, Málaga, Spain.
Background: Chronic kidney disease is a global problem characterized by a progressive decrease in kidney function with associated symptoms. A better understanding of these symptoms could lead to the development of personalized strategies.
Objective: This systematic review aims to describe the clusters of symptoms in kidney failure and categorize them according to their time of onset and how disabling they are for patients.
Titanium Dioxide (TiO) Incorporation into Poly(ether sulfone) (PES) Hollow Fiber Membranes (HFMs) Improves Biocompatibility and Separation Performance for Bioartificial Kidney (BAK) and Hemodialysis Applications.
ACS Appl Bio Mater
January 2025
Department of Chemical Engineering, Indian Institute of Technology Bombay, Mumbai 400076, India.
Hemodialysis and bioartificial kidney (BAK), which mimic both physical and biological functions, can significantly impact chronic kidney disease (CKD) patients. Here we report on Hollow fiber membranes (HFMs) with enhanced separation of uremic toxins along with enhanced hemocompatibility and biocompatibility that also promote the growth of kidney cells. The improvement arises from the addition of titanium dioxide (0.
View Article and Find Full Text PDFEvaluating Electrospun Polycaprolactone Fibers for Blood-Contacting Applications.
Biopolymers
March 2025
Department of Chemical and Materials Engineering, University of Alberta, Alberta, Canada.
When the kidneys are injured, uremic toxins (UTXs) accumulate in the body, affecting other tissues and causing a loss of essential body functions. This study investigated the adsorption of blood plasma-laden UTXs on the surface of PCL fibers to assess their potential as an alternative to membrane dialysis materials. Using plasma containing 26 UTXs at a concentration similar to that found in end-stage kidney disease patients, we analyzed the adsorbed proteins and examined clot formation in normal and toxin-treated plasma in the presence of PCL fibers.
View Article and Find Full Text PDFPeritoneal dialysis in patients with severe obesity: A successful single center experience.
Perit Dial Int
January 2025
Division of Nephrology, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
There is growing emphasis on increasing utilization of peritoneal dialysis (PD) in patients with end stage kidney disease (ESKD); however, use in patients with severe obesity has still been fraught for various reasons. We aim to assess the viability of PD in patients with severe obesity (BMI > 40 Kg/m). We conducted a retrospective chart review of patients admitted at the home dialysis center of an academic center between 2014 and 2020 (n = 99).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!